Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Inogen (INGN – Research Report), Exelixis (EXEL – Research Report) and Ultragenyx Pharmaceutical (RARE – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Inogen (INGN)
In a report released yesterday, Michael Matson from Needham reiterated a Buy rating on Inogen, with a price target of $12.00. The company’s shares closed last Monday at $6.21, close to its 52-week low of $6.14.
According to TipRanks.com, Matson is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inogen with a $13.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Exelixis (EXEL)
RBC Capital analyst Leonid Timashev maintained a Hold rating on Exelixis on January 8 and set a price target of $45.00. The company’s shares closed last Monday at $44.06.
According to TipRanks.com, Timashev is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Exelixis with a $44.09 average price target, representing a 3.5% upside. In a report released yesterday, Stifel Nicolaus also reiterated a Hold rating on the stock with a $43.00 price target.
Ultragenyx Pharmaceutical (RARE)
RBC Capital analyst Luca Issi maintained a Buy rating on Ultragenyx Pharmaceutical on January 8 and set a price target of $35.00. The company’s shares closed last Monday at $24.37.
According to TipRanks.com, Issi is a 1-star analyst with an average return of
Currently, the analyst consensus on Ultragenyx Pharmaceutical is a Strong Buy with an average price target of $61.65, implying a 168.6% upside from current levels. In a report issued on December 29, William Blair also maintained a Buy rating on the stock.
